Bluebird bio appoints new CFO amid financial restatements (updated)

bluebird bio

29/05/2024 12:27

(Adds details in paragraph 3, background in paragraph 2)
       May 29 (Reuters) - Gene therapy maker bluebird bio
 BLUE.O  on Wednesday named James Sterling as finance chief,
effective June 10, and has been tasked with overseeing a
previously announced revision of its financial statements.
    The company said in March it plans to revise its financial
statements for 2022 and the first three quarters of last year
due to accounting errors related to some contract manufacturing
deals.
        Sterling, who most recently served as the CFO of
UK-based diagnostics company Renalytix plc  RENX.L , will
succeed Chris Krawtschuk.    

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini
Ganguli and Shailesh Kuber)
 ((Mariam.ESunny@thomsonreuters.com;))